Trial · NCT03344341
A Phase IV Study in Drug-Naive Patients With T2DM in China
NCT03344341, Phase 4, Terminated, AstraZeneca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase IV Study in Drug-Naive Patients With T2DM in China. Trials, record NCT03344341. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03344341
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase IV Study in Drug-Naive Patients With T2DM in China
- NCT number
- NCT03344341
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 304 participants, actual
- Lead sponsor
- AstraZeneca
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Acarbose
- First posted
- 2017-11-17
- Last updated
- 2021-12-07
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Absolute change from baseline in HbA1c at Week 24 | At week 24 | Which will be derived using the HbA1c (%) at week 24 minus HbA1c (%) at baseline. |
| Secondary | Percentage of patients at Week 24 with reduction of HbA1c≥0.5%, body weight≥3% and SBP ≥3mmHg from baseline | From baseline to week 24 | Which will be derived using the number of patients who have reduction in HbA1c ≥ 5%, and body weight ≥3% and SBP ≥3 mmHg compared to baseline divided by the total number of patients. |
| Secondary | Percentage of patients achieving HbA1c<7.0% | From baseline to week 24 | Which will be derived using the number of patient who have the HbA1c (%) \< 7.0% after 24 weeks treatment divided by the total number of patients. |
| Secondary | Percentage of patients with reduction of HbA1c≥0.5% | From baseline to week 24 | Which will be derived using the number of patients who have reduction in HbA1c≥0.5% after 24 weeks compared to baseline divided by the total number of patients. |
| Secondary | Absolute change from baseline in fasting plasma glucose (FPG) | From baseline to week 24 | Which will be derived using the value of fasting plasma glucose (FPG) at post-baseline visits minus the value at baseline |
| Secondary | Absolute change from baseline in 2h postprandial glucose (PPG) | From baseline to week 24 | Which will be derived using the value of 2h postprandial glucose (PPG) at the post-baseline visits minus the value at baseline |
| Secondary | Absolute change from baseline in body weight | From baseline to week 24 | Which will be derived using the value of the body weight at the post-baseline visits minus the value at baseline |
| Secondary | Percentage of patients with reduction of body weight ≥3% | From baseline to week 24 | Which will be derived using the number of patients who have reduction in body weight≥3% after 24 weeks compared to baseline divided by the total number of patients. |
| Secondary | Absolute change from baseline in systolic blood pressure (SBP) | From baseline to week 24 | Which will be derived using the value of the systolic blood pressure at the post-baseline visits minus the value at baseline |
| Secondary | Percentage of patients with reduction of SBP ≥3 mmHg | From baseline to week 24 | Which will be derived using the number of patients who have reduction in SBP ≥3 mmHg after 24 weeks compared to baseline divided by the total number of patients. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03344341
GET https://conductscience.org/api/trials/v1/NCT03344341/registered